Robert M. Wenham, MD

Articles

Dr. Wenham on the Role of ADCs in Ovarian Cancer

June 20th 2022

Robert Wenham, MD, MS, FACOG, FACS, discusses the role of antibody-drug conjugates in ovarian cancer.

Dr. Wenham on the Potential for Immunotherapy in Ovarian Cancer

August 31st 2021

Robert Wenham, MD, MS, FACOG, FACS, discusses the potential for immunotherapy in ovarian cancer.

Dr. Wenham on Future Directions with Antibody-Drug Conjugates in Ovarian Cancer

March 30th 2021

Robert Wenham, MD, MS, FACOG, FACS, discusses future directions with antibody-drug conjugates in the treatment of patients with ovarian cancer.

Dr. Wenham on Rationale for Novel Immunotherapy Combos in Ovarian Cancer

February 24th 2021

Robert Wenham, MD, MS, FACOG, FACS, discusses novel immunotherapy combinations for the treatment of patients with ovarian cancer.

Dr. Wenham on Trials Evaluating IP, IV, and Dose-Dense Chemotherapy in Ovarian Cancer

February 26th 2020

Robert M. Wenham, MD, gynecologic oncologist and chair of the Gynecologic Oncology Program at Moffitt Cancer Center, discusses data with intraperitoneal (IP) chemotherapy, dose-dense chemotherapy, and intravenous (IV) chemotherapy in patients with advanced ovarian cancer.

Dr. Wenham on Neoadjuvant Chemotherapy Versus Primary Debulking Surgery in Ovarian Cancer

February 19th 2020

Robert M. Wenham, MD, gynecologic oncologist and chair of the Department of Gynecologic Oncology at Moffitt Cancer Center, sheds light on the debate between neoadjuvant chemotherapy and primary debulking surgery in patients with newly diagnosed, advanced ovarian cancer.